esta vez con la construcción de una nueva granja solar ubicada en la provincia de Coclé en Panamá, que cuenta con una capacidad de 3,8 MWp y una generación estimada de 5.750 kW/h al año.

VANCOUVER, British Columbia and BOSTON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc ... of azetukalner with our first Phase 3 trial in MDD expected to initiate by year-end ...

Xenon has advanced its Phase 3 clinical trials for epilepsy, with the X-TOLE2 topline data expected in the latter half of 2025. The company also plans to initiate the X-NOVA2 study for MDD by the ...

About the Azetukalner Phase 3 Epilepsy Program Xenon’s Phase 3 epilepsy program includes three ongoing Phase 3 clinical trials in focal onset seizures (FOS) and primary generalized tonic-clonic ...

BURNABY, British Columbia (AP) — BURNABY, British Columbia (AP) — Xenon Pharmaceuticals Inc. (XENE) on Tuesday reported a loss of $62.8 million in its third quarter. The Burnaby, British ...

X-NOVA2, the first of three Phase 3 clinical trials evaluating azetukalner in patients with MDD, is expected to initiate before the end of the year. Xenon presented Phase 2 X-NOVA data at the Psych ...

At this time, I'd like to welcome everyone to Xenon Pharmaceuticals ... continuing the execution of our Phase 3 azetukalner epilepsy program while raising the profile of azetukalner with both ...

VANCOUVER, British Columbia and BOSTON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq ... in the broader applicability of azetukalner with our first Phase 3 trial in MDD ...

Xenon had cash, cash equivalents and marketable securities worth $803.3 million as of Sept. 30, 2024, compared with $850.6 million as of June 30, 2024. The company expects its existing cash ...

“Xenon’s leadership in the Kv7 landscape is unmatched as our lead molecule, azetukalner, represents the only highly potent, selective Kv7 potassium channel opener in development for multiple ...